Updates are available Correction dated 2022-05-21
Click to view Correction: https://doi.org/10.1186/s13195-022-00995-9
-
Authors
Swanson, Chad J.
Zhang, Yong
Dhadda, Shobha
Wang, Jinping
Kaplow, June
Lai, Robert Y. K.
Lannfelt, Lars
Bradley, Heather
Rabe, Martin
Koyama, Akihiko
Reyderman, Larisa
Berry, Donald A.
Berry, Scott
Gordon, Robert
Kramer, Lynn D.
Cummings, Jeffrey L. http://orcid.org/0000-0001-8944-4158
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (P20GM109025)
National Institute of Neurological Disorders and Stroke (U01NS093334)
National Institute on Aging (R01AG053798, P20AG068053)
- License Information
-
More Information
Article History
Received: 21 December 2020
Accepted: 23 March 2021
First Online: 17 April 2021
Change Date: 22 March 2023
Change Type: Update
Change Details: The paper was revised: Supplementary label was changed to "Additional Supplemental Files", and the naming of Supplementary files was amended to match with the contents of each file.
Change Details: The original version of this article was revised: files for Supplementary Appendices A and B were not included in the publication of the original article.
Change Date: 21 May 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13195-022-00995-9
Declarations
:
: The trial was approved by the institutional review board or independent ethics committee at each center and all subjects provided informed consent.
: Not applicable.
: CJS, YZ, SD, JW, JK, RYKL, HB, MR, AK, LR, RG, and LDK are employees of Eisai. LL is an employee of BioArctic. DAB and SB are employees of Berry Consultants. JLC provided consultation to the following pharmaceutical companies: Acadia, Accera, Actinogen, ADAMAS, Alkahest, Allergan, Alzheon, Avanir, Axovant, Axsome, BiOasis Technologies, Biogen, Eisai, Genentech, Grifols, Kyowa, Lilly, Lundbeck, Merck, Nutricia, Otsuka, QR Pharma, Resverlogix, Roche, Samus, Servier, Suven, Takeda, Toyoma, and United Neuroscience companies. JLC is supported by NIGMS grant P20GM109025; NINDS grant U01NS093334; NIA grant R01AG053798; and NIA grant P20AG068053.
